Tumor DNA Platform Classifies Colorectal Cancer
By LabMedica International staff writers Posted on 15 Jan 2020 |
Image: Schematic diagram of, circulating tumor DNA (ctDNA); circulating tumor cell (CTC); cell-free DNA (cfDNA) in the peripheral blood stream of a colon cancer patient (Photo courtesy of Oncology Letters)
Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders. Some of the inherited genetic disorders that can cause colorectal cancer include familial adenomatous polyposis and hereditary non-polyposis colon cancer; however, these represent less than 5% of cases.
The detection of circulating tumor DNA in the blood is a noninvasive method that may help detect cancer at early stages if the correct markers for evaluation are known. A new machine learning platform can identify patients with colorectal cancer (CRC) and helps predict their disease severity and survival.
Scientists at the Sun Yat-sen University Cancer Center (Guangzhou, China) and their colleagues first identified CRC-specific methylation signatures by comparing CRC tissues to normal blood leukocytes. They then created a diagnostic model based on nine methylation markers associated with colorectal cancer, which they identified by studying plasma samples from 801 patients with colorectal cancer as well as 1,021 controls.
This model accurately distinguished patients from healthy individuals with a sensitivity and specificity of 87.5% and 89.9%, respectively, and outperformed a clinically available blood test named serum carcinoembryonic antigen (CEA). Furthermore, a modified prognostic model helped predict the patients' risk of death over a follow-up period of 26.6 months on average, especially when combined with established clinical characteristics such as tumor location. The team found that a single circulating tumor DNA methylation marker, cg10673833, could yield high sensitivity (89.7%) and specificity (86.8%) for detection of CRC and precancerous lesions in a high-risk population of 1,493 participants in a prospective cohort study.
The authors concluded that they had showed the value of circulating tumor DNA (ctDNA) methylation markers in the diagnosis, surveillance, and prognosis of CRC. The study was published on January 1, 2020 in the journal Science Translational Medicine.
Related Links:
Sun Yat-sen University Cancer Center
The detection of circulating tumor DNA in the blood is a noninvasive method that may help detect cancer at early stages if the correct markers for evaluation are known. A new machine learning platform can identify patients with colorectal cancer (CRC) and helps predict their disease severity and survival.
Scientists at the Sun Yat-sen University Cancer Center (Guangzhou, China) and their colleagues first identified CRC-specific methylation signatures by comparing CRC tissues to normal blood leukocytes. They then created a diagnostic model based on nine methylation markers associated with colorectal cancer, which they identified by studying plasma samples from 801 patients with colorectal cancer as well as 1,021 controls.
This model accurately distinguished patients from healthy individuals with a sensitivity and specificity of 87.5% and 89.9%, respectively, and outperformed a clinically available blood test named serum carcinoembryonic antigen (CEA). Furthermore, a modified prognostic model helped predict the patients' risk of death over a follow-up period of 26.6 months on average, especially when combined with established clinical characteristics such as tumor location. The team found that a single circulating tumor DNA methylation marker, cg10673833, could yield high sensitivity (89.7%) and specificity (86.8%) for detection of CRC and precancerous lesions in a high-risk population of 1,493 participants in a prospective cohort study.
The authors concluded that they had showed the value of circulating tumor DNA (ctDNA) methylation markers in the diagnosis, surveillance, and prognosis of CRC. The study was published on January 1, 2020 in the journal Science Translational Medicine.
Related Links:
Sun Yat-sen University Cancer Center
Latest Pathology News
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes
- Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases